OPKHealthcare · Diagnostics & ResearchThe 6 Wall Street analysts covering OPKO Health, Inc. hold a median 12-month price target of $3 — +97.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 31 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores OPKO Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (91): Sales and profits are climbing, and climbing faster than before.
Value (29): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OPK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +97.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Apr 2026 | Barrington Research | Downgrade | Market Perform | — |
| 2 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 20 Nov 2025 | JP Morgan | Initiates | Neutral | — |
| 31 Oct 2025 | Jefferies | Downgrade | Hold | — |
| 30 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 1 May 2025 | Barrington Research | Maintains | Outperform | — |
| 25 Apr 2025 | JP Morgan | Initiates | Neutral | — |
| 7 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Mar 2025 | Barrington Research | Maintains | Outperform | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Feb 2025 | Barrington Research | Maintains | Outperform | — |
| 8 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Nov 2024 | Barrington Research | Maintains | Outperform | — |
| 26 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2024 | Barrington Research | Maintains | Outperform | — |
| 17 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Sept 2024 | Piper Sandler | Reiterates | Overweight | — |
| 8 Aug 2024 | Barrington Research | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OPK appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 1 Sept 2026, OPKO Health, Inc. returned +10.1% against +19.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 55% of US stocks
Cheaper than 76% of US stocks
Cheaper than 87% of US stocks
Higher than 37% of US stocks
Higher than 41% of US stocks
Higher than 61% of US stocks
Higher than 23% of US stocks
Higher than 19% of US stocks
Higher than 39% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OPKO Health, Inc. has a market value of $1.1B and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $587.9M. The latest quarter grew 4.3% year on year.
Net income over the same four quarters: −$72.9M, a −12.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.09.
Free cash flow in the twelve months to 30 June 2026: −$134.0M, after $10.6M of capital spending.
OPKO Health, Inc. spent $46.6M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −5.1×; forward P/E: −5.5× — the forward figure prices analyst consensus estimates, not reported earnings.
OPKO Health, Inc. employs 2,275 people — $258K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OPKO Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
OPKO Health (OPK) reported earnings 30 days ago, and its stock is down 9.7% since that earnings report. The item notes that the company's next move for the stock is being watched.
Why it matters — An OPK watcher would care because the stock has declined notably in the month following the latest earnings report, with attention now on what comes next for the company.
Zacks Investment Research advises investors to retain OPKO Health stock, citing a growth outlook supported by RAYALDEE, strategic partnerships, BioReference restructuring, and multiple pipeline catalysts.
Why it matters — OPK watchers would care because the report highlights the company's current product, partnerships, restructuring, and pipeline as factors supporting its outlook.
OPKO Health secured $125 million in royalty-backed financing, providing non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
Why it matters — The financing adds capital without diluting existing shareholders while keeping OPK's upside from mazdutide in China intact.
A Zacks Investment Research article examines whether OPKO Health is worth buying as its valuation meets improving business trends, noting the company pairs a discounted forward sales multiple with narrowing losses and partnership support, while early-stage clinical risk keeps the investment case balanced.
Why it matters — OPK watchers would care because the analysis weighs improving financial and partnership trends against ongoing early-stage clinical risk in assessing the company's outlook.
OPKO Health's stock rose 12.4% over the past month, a gain the report attributes to narrower losses and improved margins. The report also notes that profitability and clinical execution remain key risks going forward.
Why it matters — The monthly stock gain and improved financial metrics offer OPK watchers a current snapshot of the company's performance, while the highlighted risks of profitability and clinical execution point to factors likely to shape its outlook.
The 6 Wall Street analysts covering OPKO Health, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $8.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering OPKO Health, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OPKO Health, Inc. 75 out of 100 across roughly 4,600 US stocks as at 31 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Aug 2026, OPKO Health, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +97.4% from the last close, and Ticker Nerd's factor model ranks OPKO Health, Inc. 75 out of 100 as at 31 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OPKO Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $8.5 over the next 12 months.
OPKO Health, Inc. returned +10.1% over the 12 months to 1 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals.
The most recent item we track (Zacks Investment Research, 26 Aug 2026): "Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?". OPKO Health (OPK) reported earnings 30 days ago, and its stock is down 9.7% since that earnings report. The item notes that the company's next move for the stock is being watched.
OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals. Through its Diagnostics segment, the company provides clinical laboratory and genetic testing services, including BioReference Health and specialized assays used in disease detection, monitoring, and patient management. Its Pharmaceutical segment markets approved therapies and supports development programs across areas such as kidney disease, hormone-related disorders, oncology, and infectious diseases. OPKO Health also works with commercial partners and maintains manufacturing, supply, and research activities across several international markets. The company plays a broad role in the healthcare market by combining testing services, marketed medicines, and pipeline assets within a single operating platform. OPKO Health, Inc. is headquartered in Miami, Florida.
CEO Dr. Phillip Frost M.D., Ph.D. · 2,275 employees · United States · https://www.opko.com
